A 'Big Data' Approach to Developing Cancer Drugs

Scientists are starting to accumulate huge datasets on which genes mutate during cancer, allowing for a more systematic approach to "precision medicine." In a study published in Cell, researchers compared genetic mutations in patient tumors to those in cancer cell lines and then tested the cell lines' responses to therapeutic compounds. By analyzing where these datasets overlap, researchers can begin to predict on a large scale which drugs will best fight various cancers.

"The process that we've done, by nature, is a discovery process," says Mathew Garnett, a cancer biologist at the Wellcome Trust Sanger Institute. "It's the beginning of generating exciting new ideas about how we might target specific patient populations with specific drugs. This type of study wasn't possible a few years ago because we hadn't sequenced enough patient tumors."

When developing new anti-cancer drugs, researchers often rely first on cancer cell lines in the lab. "You can't screen hundreds of drugs across a single patient. It's not possible," says Ultan McDermott, a cancer clinician and researcher also at the Sanger Institute. "But you can do that with cell lines--you can expose them to many different drugs and ask questions about which is more or less sensitive."

How closely these cell lines match what actually happens in a human tumor has been unclear, however, and previous efforts to model drug response using cancer cell lines were done on a relatively small scale. To investigate a larger piece of the landscape, Garnett, McDermott, and their colleagues analyzed data from two public datasets, The Cancer Genome Atlas and the International Cancer Genome Consortium, and other studies, gathering genetic information for more than 11,000 tumor samples.

The team then compared these tumor samples to about 1,000 cancer cell lines used in labs, looking for lines that had the same types of mutations as the patient samples - and therefore might more closely mimic patient responses. "Many of the cell lines do capture the molecular features that are important to human beings in cancer," says McDermott.

Once they mapped the tumor mutations onto the cell lines, the researchers looked for the genetic mutations that could best predict the cancer cells' response to 265 different anti-cancer compounds at various stages of development. The drugs covered a range of mechanisms, including chemotherapeutics, small-molecule inhibitors, epigenetic modulators, and cell death regulators.

Many of the mutations that occurred both in tumor samples and cell lines did signal whether the cancer cells would be sensitive or resistant to different compounds, largely depending on the type of tissue the cancer originated in. "If you can identify the clinically relevant features in cell lines and correlate those with drug response, you're one step closer to identifying a drug interaction that could be important for a patient," says McDermott.

"We've taken a leap forward in doing this type of study in a very comprehensive and systematic way, as opposed to what often is done, where someone might do it with a single drug or in a single cell line," explains Garnett. "It's by no means the end of the journey--but it's a huge milestone."

Going forward, the researchers are creating a web portal to share their data, which will allow cancer researchers to see which cell lines most closely mirror the patient condition they aim to emulate and how those cell lines respond to different drugs. Garnett and McDermott's teams are also starting their own follow-up projects to investigate associations between certain cell mutations and drug effects, with the hope of more clearly pinpointing which cancer patients will most benefit from a given compound.

This study was supported by the Wellcome Trust, the European Bioinformatics Institute and Wellcome Trust Sanger Institute post-doctoral programs, the National Cancer Institute, the Netherlands Organization for Scientific Research, the People Programme (Marie Curie Actions) of the 7th Framework Programme of the European Union, the Agency of Competitiveness for Companies of the Government of Catalonia, La Fundació la Marató de TV3, the European Research Council, the Ministerio de Ciencia e Innovacion, the Institute of Health Carlos III, the Spanish Cancer Research Network, the Health and Science Departments of the Catalan Government, the Cellex Foundation, and a Cancer Research UK Clinician Scientist Fellowship.

Cell, Iorio et al.: "A landscape of pharmacogenomic interactions in cancer" http://www.cell.com/cell/fulltext/S0092-8674(16)30746-2

Cell (@CellCellPress), the flagship journal of Cell Press, is a bimonthly journal that publishes findings of unusual significance in any area of experimental biology, including but not limited to cell biology, molecular biology, neuroscience, immunology, virology and microbiology, cancer, human genetics, systems biology, signaling, and disease mechanisms and therapeutics.

Most Popular Now

MEDICA 2024 + COMPAMED 2024: Adapted Hal…

11 - 14 November 2024, Düsseldorf, Germany. The final preparations for MEDICA 2024 and COMPAMED 2024 in Düsseldorf have begun. A total of more than 5,500 exhibitors from approximately 70 countries...

AI does Not Necessarily Lead to more Eff…

The use of artificial intelligence (AI) in hospitals and patient care is steadily increasing. Especially in specialist areas with a high proportion of imaging, such as radiology, AI has long...

Commission Joins Forces with Venture Cap…

The Commission has launched a Trusted Investors Network bringing together a group of investors ready to co-invest in innovative deep-tech companies in Europe together with the EU. The Union's investment...

Why the NHS is Seeking to Make Media Ser…

Opinion Article by Dean Moody, Healthcare Services Director, Airwave Healthcare. Tim Kelsey and Martha Lane Fox called for WiFi to be made available free of charge throughout the NHS back in...

An AI-Powered Pipeline for Personalized …

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses...

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

Wearable Cameras Allow AI to Detect Medi…

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence (AI), detects potential errors in medication delivery. In a test whose...

AI could Transform How Hospitals Produce…

A pilot study led by researchers at University of California San Diego School of Medicine found that advanced artificial intelligence (AI) could potentially lead to easier, faster and more efficient...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

Great Start for Ideas and Innovations: D…

8 - 10 April 2025, Berlin, Germany. From 15 October to 15 November 2024, the DMEA invites experts from business, science, politics and practice to actively participate in shaping the congress...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...